Pargyline HCl

产品说明书

Print
Chemical Structure| 306-07-0 同义名 : 优降宁盐酸盐 ;Pargyline (hydrochloride);Pargyline hydrochloride;Pargyline;N-Methyl-N-propargylbenzylamine hydrochloride;Eutonyl-ten;N-benzyl-N-methylprop-2-yn-1-amine hydrochloride;NSC 43798;Pargylamine hydrochloride
CAS号 : 306-07-0
货号 : A200574
分子式 : C11H14ClN
纯度 : 99%+
分子量 : 195.69
MDL号 : MFCD00012492
存储条件：

Pure form Inert atmosphere,Store in freezer, under -20°C

In solvent -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 120 mg/mL(613.21 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

H2O: 100 mg/mL(511.01 mM)，配合低频超声助溶
动物实验配方：
生物活性
靶点

  • MAO-B

    MAO-B, Ki:0.5 μM

  • MAO-A

    MAO-A, Ki:13 μM
描述 Pargyline hydrochloride is an irreversible monoamine oxidase (MAO) inhibitor with Kis of 13 μM and 0.5 μM for MAO-A and MAO-B, respectively[2]. Pargyline (0.5-2 mM; 24-120 hours; LNCaP-LN3 cells) treatment inhibits the proliferation of prostate cancer cells in a time- and dose-dependent manner. Pargyline (0.5-2 mM; 24-48 hours; LNCaP-LN3 cells) treatment decreases S phase and increases the G1 phase in the cells in a dose-dependent manner. Pargyline (0.5 mM; 24 hours; LNCaP-LN3 cells) treatment increases the apoptotic cells. Pargyline (2 mM; 48 hours; LNCaP-LN3 cells) treatment induces an increase of cytochrome c and a decrease of caspase-3 in the cells, but does not lead to a change of BCL-2 expression[3]. Moreover, a low dose of pargyline injected directly into the brain lowered arterial pressure[4]. Pargyline decrease STEP (striatal-enriched protein tyrosine phosphatase) activity in the D. rerio brain, without affecting the level of the ptpn5 mRNA gene[5]. Pargyline (100 mg/kg) increased the concentration of cerebral noradrenaline dopamine and 5-hydroxytryptamine in the mouse[6].
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

5.11mL

1.02mL

0.51mL

25.55mL

5.11mL

2.56mL

51.10mL

10.22mL

5.11mL
参考文献

[1]Bianchi P, et al. A new hypertrophic mechanism of serotonin in cardiac myocytes: receptor-independent ROS generation. FASEB J. 2005 Apr;19(6):641-3.

[2]Fowler CJ, Mantle TJ, Tipton KF. The nature of the inhibition of rat liver monoamine oxidase types A and B by the acetylenic inhibitors clorgyline, l-deprenyl and pargyline. Biochem Pharmacol. 1982 Nov 15;31(22):3555-61

[3]Lee HT, Choi MR, Doh MS, Jung KH, Chai YG. Effects of the monoamine oxidase inhibitors pargyline and tranylcypromine on cellular proliferation in human prostate cancer cells. Oncol Rep. 2013 Oct;30(4):1587-92

[4]Fuentes JA, Ordaz A, Neff NH. Central mediation of the antihypertensive effect of pargyline in spontaneously hypertensive rats. Eur J Pharmacol. 1979 Jul 15;57(1):21-7

[5]Kulikova EA, Fursenko DV, Bazhenova EY, Kulikov AV. [Decrease in the Activity of Striatal-Enriched Protein-Tyrosine-Phosphatase (STEP) in the Brain of Danio rerio Treated with p-Chlorophenylalanine and Pargyline]. Mol Biol (Mosk). 2021 Jul-Aug;55(4):660-666. Russian

[6]Hutchins DA. The effect of pargyline and desmethylimipramine on monoamine concentrations and amphetamine-induced glycogenolysis in the mouse brain. Br J Pharmacol. 1979 Mar;65(3):489-94